8-K: Scienture Holdings Enters Consulting Agreement with Draper, Inc. and Announces FDA Approval of Arbli™

Scienture Holdings, Inc. announces a consulting agreement with Draper, Inc. for investor relations and business development, and the FDA approval of Arbli™ (losartan potassium) Oral Suspension.

Summary

• Scienture Holdings, Inc. entered into a consulting agreement with Draper, Inc. on March 17, 2025, for investor relations and business development services.
• The consulting agreement has an initial term of three months and automatically renews for successive one-month terms until terminated with seven days' notice.
• Draper will receive 100,000 restricted shares of Scienture's common stock upon execution of the agreement and an additional 100,000 shares for each subsequent term.
• On March 18, 2025, Scienture announced that the FDA approved its NDA for SCN-102, to be launched as Arbli™ (losartan potassium) Oral Suspension, 10mg/mL.
• Arbli™ is the first and only FDA-approved ready-to-use oral liquid losartan in the U.S. market.
• The global market for losartan potassium was approximately $1.5 billion in sales in 2024.
• IQVIA data (MAT December 2024) indicates a total annual sales of approximately $292 million and a prescription volume of 68 million (TRx) for losartan in the US market.
• Scienture expects to commercially launch Arbli™ in the U.S. in Q3 2025.

Sentiment

Score: 7

Explanation: The document presents a mix of positive news (FDA approval) and potential risks (dilution from stock issuance, market competition). The overall sentiment is moderately positive due to the significant regulatory milestone.

Positives

• The consulting agreement with Draper, Inc. aims to enhance investor relations and business development.
• FDA approval of Arbli™ provides Scienture with a unique product in the losartan market.
• Arbli™ addresses the need for a safe and convenient liquid formulation of losartan, eliminating the risks associated with compounding.
• Arbli™ has two issued patents from the USPTO, which are also expected to be listed in the FDA Orangebook.
• Arbli™ has been approved for a shelf life of 18 months from the date of manufacture when stored at room temperature, based on the data submitted in the NDA.
• Once the 24-months stability data is submitted to the FDA, the shelf-life of the product is expected to be extended to 24-months at room temperature.

Negatives

• The consulting agreement requires the issuance of a significant number of restricted shares, potentially diluting existing shareholders' equity.
• The press release contains forward-looking statements that are subject to risks and uncertainties, and actual results may differ materially.
• Arbli™ is indicated for hypertension, to lower blood pressure in adults and children greater than 6 years old.
• Arbli™ is indicated for reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy.
• Arbli™ is indicated for treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension.
• ArbliTM can cause fetal harm when administered to a pregnant woman.
• ArbliTM has not been studied in patients with severe hepatic impairment.
• The most common adverse reactions are (incidence 2% and greater than placebo): dizziness, upper respiratory infection, nasal congestion, and back pain.

Risks

• The success of Arbli™ depends on its commercial launch and market acceptance in Q3 2025.
• The company's future financial performance is subject to risks and uncertainties, as detailed in its SEC filings.
• The company's ability to raise funding in the future is uncertain and could result in dilution.
• The company faces risks related to agreements with third parties and potential claims relating to intellectual property rights.
• The company faces risks relating to its ability to maintain the listing of its common stock on the Nasdaq Capital Market.

Future Outlook

Scienture expects to commercially launch Arbli™ in the U.S. in Q3 2025 and anticipates it will address unmet patient needs. The company also has an upcoming pipeline of novel specialty products.

Management Comments

• Shankar Hariharan, CEO of Scienture, LLC, remarked that the approval of Arbli™ exemplifies their deep commitment to develop high-value products that address unique and underserved patient needs.
• Narasimhan Mani, President of Scienture, LLC, stated that they are pleased to bring to market Arbli™, a transformative therapy option containing losartan.
• Suren Ajjarapu, Chairman of the Board, Scienture Holdings, Inc., said that the announcement is extremely exciting and is a clear demonstration of the value Scienture, LLC brings to the combined company and its shareholders.

Industry Context

The FDA approval of Arbli™ positions Scienture in the hypertension treatment market, competing with existing oral solid losartan products. Arbli™ differentiates itself as the first ready-to-use liquid formulation, potentially capturing market share from compounded losartan prescriptions.

Comparison to Industry Standards

• The global losartan potassium market was approximately $1.5 billion in sales in 2024.
• IQVIA data (MAT December 2024) indicates a total annual sales of approximately $292 million and a prescription volume of 68 million (TRx) for losartan in the US market.
• Competitors like Teva Pharmaceuticals and Mylan offer losartan tablets, but Arbli™ is the first FDA-approved liquid formulation, giving it a competitive edge.

Stakeholder Impact

• Shareholders may benefit from the potential revenue generated by Arbli™ and the enhanced investor relations efforts.
• Patients gain access to a convenient and safe liquid formulation of losartan.
• Healthcare professionals have a new treatment option for hypertension and related conditions.

Next Steps

• Scienture will commercially launch Arbli™ in the U.S. in Q3 2025.
• Scienture will submit the 24-months stability data to the FDA, the shelf-life of the product is expected to be extended to 24-months at room temperature.

Key Dates

Keywords

Arbli, losartan potassium, FDA approval, consulting agreement, Draper Inc., Scienture Holdings, investor relations, business development, pharmaceutical, hypertension